Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Equivalents: 2013-2024

Historic Cash & Equivalents for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $143.4 million.

  • ImmunityBio's Cash & Equivalents fell 46.20% to $60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.2 million, marking a year-over-year decrease of 46.20%. This contributed to the annual value of $143.4 million for FY2024, which is 45.97% down from last year.
  • According to the latest figures from FY2024, ImmunityBio's Cash & Equivalents is $143.4 million, which was down 45.97% from $265.5 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Cash & Equivalents ranged from a high of $265.5 million in FY2023 and a low of $34.9 million during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $143.4 million (2024), whereas its average is $171.2 million.
  • As far as peak fluctuations go, ImmunityBio's Cash & Equivalents crashed by 53.94% in 2020, and later soared by 418.69% in 2021.
  • Over the past 5 years, ImmunityBio's Cash & Equivalents (Yearly) stood at $34.9 million in 2020, then spiked by 418.69% to $181.1 million in 2021, then tumbled by 42.22% to $104.6 million in 2022, then spiked by 153.68% to $265.5 million in 2023, then plummeted by 45.97% to $143.4 million in 2024.